Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lutein and zeaxanthin are xanthophyll carotenoids that accumulate in the macula and retina, particularly in a region responsible for high-acuity vision. They act as potent antioxidants and filter short-wavelength (especially blue) light, thereby reducing oxidative and photo-induced retinal damage. Their presence is hypothesized to protect against age-related macular degeneration, cataracts, and other retinal diseases. Lutein and zeaxanthin cannot be synthesized by the human body and must be obtained from the diet. While promising as preventive nutrients for retinal health, they are not conventional drug targets such as receptors or enzymes, but rather function as biological pigments that support retinal integrity.
As supplements, lutein and zeaxanthin function via direct antioxidant activity and absorption of short-wavelength (blue) light to reduce photochemical and oxidative retinal damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lutein (and Zeaxanthin).